Dark-blue-pieces-abstract-background

Press Releases

Announcements in the Media

You are here: Home / News / Press Releases

May 24

2017

SAN DIEGO, May 24, 2017 – Edico Genome today announced it has collaborated with Illumina to make DRAGEN™ available on BaseSpace® Sequence Hub. DRAGEN delivers extremely high accuracy at ultra-rapid speeds, enabling a whole human genome to be analyzed in under 10 minutes.

May 9

2017

SAN DIEGO, May 9, 2017 – Edico Genome announced today it has raised $22 million in a Series B financing to expand market adoption and product development of its DRAGEN™ platform, an end-to-end solution for analysis of next-generation sequencing data. New investor Dell Technologies Capital, the venture arm of Dell Technologies, led the round and all existing investors participated, including Qualcomm Ventures, Axon Ventures and life sciences industry executive Greg Lucier.

April 20

2017

SAN DIEGO and CAMBRIDGE, ENGLAND – April 19, 2017 Congenica and Edico Genome today announced the companies have partnered to offer their complementary platform technologies as an all-in-one, genome data analysis solution that accelerates clinical labs’ and hospitals’ progression from DNA sequencing to diagnosis for inherited diseases, which otherwise can take months or years, while also reducing costs.

March 20

2017

Company Holds Largest IP Portfolio Encompassing Processor-Based Analysis of Next-Generation Sequencing Data

SAN DIEGO, March 20, 2017 – Edico Genome, creator of the world’s first processor designed to analyze next-generation sequencing data, today announced the United States Patent and Trademark Office has issued an additional five, foundational patents surrounding the DRAGEN™ platform for analysis and storage of genomic data. Edico’s intellectual property portfolio now contains eight issued patents, which provide protection up to 2033. An additional sixteen patents are pending.

February 5

2017

SAN DIEGO, Feb. 15, 2017 – Edico Genome, creator of an end-to-end platform solution for analysis of next-generation sequencing data, today announced it was named a winner of an IBM Choice Award for 2017 North America Top Independent Software Vendor. Honored at the IBM PartnerWorld Leadership Conference in Las Vegas, Edico Genome was recognized for its secure, scalable, public platform for virtual or onsite ultra-rapid analysis of next-generation sequencing data. By utilizing DRAGEN technology deployed in IBM’s SoftLayer cloud, users of the technology can analyze their genomic data in just minutes. In addition, existing users of onsite DRAGEN systems can now operate as part of a secure hybrid cloud with the flexibility to scale up to the cloud during times of high capacity and return to onsite analysis when demand is reduced.

January 4

2017

Dell EMC Storage

SAN DIEGO, January. 04, 2017 – Edico Genome, creator of the world’s first bio-IT processor designed to analyze next-generation sequencing data, today announced a collaboration with Dell EMC to offer a bundled compute and storage solution for rapid, cost-effective and accurate analysis of next-generation sequencing data. The highly optimized solution includes Edico Genome’s DRAGENTM processor integrated into a 1U Dell 4130 server for ultra-rapid genome analysis and Dell EMC’s Isilon scale-out networked attached storage (NAS) for ultra-efficient genomic data storage across all levels of throughput capacity.

November 30

2016

SAN DIEGO, Nov. 30, 2016 – Edico Genome, creator of the world’s first bio-IT processor designed to analyze next-generation sequencing data, today announced that they are deploying DRAGEN on AWS’ newly available Amazon EC2 F1 instances, which are Field Programmable Gate Array (FPGA)-enabled instances in the cloud, potentially reducing analysis times from 26 minutes for a whole genome to real time.

October 14

2016

SAN DIEGO, Oct. 14, 2016 – Researchers from Rady Children’s Institute for Genomic Medicine and Edico Genome have worked together in successfully demonstrating ultra-rapid, 26-hour whole-genome based diagnoses of critically ill newborns in the neonatal intensive care unit (NICU) and pediatric intensive care unit (PICU). The ultra-rapid NICU whole-genome test is powered by Edico Genome’s DRAGEN™, the world’s first bio-IT processor designed to rapidly accelerate the analysis of genomic data while maintaining high accuracy. Rady Children’s Institute for Genomic Medicine and Edico Genome will work together to evolve the DRAGEN platform to impact additional areas of clinical genome analysis. This vision includes scaling the ultra-rapid NICU testing to additional NICUs and PICUs utilizing an all-in-one appliance deployed onsite or in the cloud and including analysis of additional clinically relevant variant types.

October 14

2016

SAN DIEGO, Oct. 14, 2016 – Edico Genome today announced that Johns Hopkins Genomics, a new entity combiningJohns Hopkins University’s research and clinical genomics services, has acquired Edico Genome’s DRAGEN™ Bio-IT Processor in order to further evaluate its utility in meeting an increased demand for whole genome and whole exome sequencing. DRAGEN’s pipelines will be evaluated for integration into existing workflows and for utilization across the institute to support the upsurge in both research and clinical testing by rapidly accelerating analysis times and reducing storage requirements.

October 6

2016

Genewiz Logo

SOUTH PLAINFIELD, N.J. and SAN DIEGO – Oct. 6, 2016 – GENEWIZ, a leading global genomics services provider, today announced it will implement multiple Edico Genome DRAGEN™ Bio-IT Processors to accelerate the analysis of massive volumes of genomic data generated by its high-throughput sequencing platforms. GENEWIZ’s already quick turnaround times are expected to be reduced by days for large next-generation sequencing (NGS) data sets, without sacrificing data quality or integrity.

September 20

2016

DRAGEN’s Speed and Accuracy to be Applied Across Baylor Genetics’ Test Portfolio

HOUSTON and SAN DIEGO, Sept. 20, 2016 – Baylor Genetics, a genetics laboratory specializing in the development and commercialization of the highest quality genetic and genomic testing, today announced it has selected Edico Genome’s DRAGEN™ Bio-IT Processor to accelerate test turnaround time in clinical settings. DRAGEN will support Baylor Genetics’ extensive testing portfolio, including its GeneAware reproductive carrier screen, rare disease diagnostic testing and whole exome sequencing test. Rapid turnaround times allow Baylor Genetics Laboratories’ physicians and genetic counselors to communicate results to patients faster, enabling treatment decisions to be made as quickly as possible.

August 1

2016

Baylor College of Medicine Genetics Study

Authored by Baylor College of Medicine, Results Published in Cell Systems and Introduce Open-Source Juicer Tool

SAN DIEGO, August 1, 2016 —Edico Genome’s DRAGEN™ Bio-IT processor accelerated by nearly 20-fold the analysis of massive data sets generated from the study of three-dimensional (3-D) structures of DNA, as published in Cell Systems. In the paper, Dr. Erez Lieberman Aiden, assistant professor of molecular and human genetics and director of The Center for Genome Architecture (TC4GA) at Baylor College of Medicine and Rice University, and his colleagues introduced Juicer, an open-source tool for used in three-dimensional (3-D) genome sequencing (“Hi-C”) experiments.

May 19

2016

SAN DIEGO, May 19, 2016 —Edico Genome, creator of the world’s first bio-IT processor designed to analyze next-generation sequencing (NGS) data, today announced a third, foundational patent issued by the United States Patent and Trademark Office. U.S. patent number 14/948372, entitled “Bioinformatics Systems, Apparatuses, And Methods Executed On An Integrated Circuit Processing Platform,” broadly covers the technology and methods of use that are core to the DRAGEN™ Bio-IT Processor, including the hardware processing platform and its use for executing a sequence analysis pipeline on genomic data for both onsite and cloud deployment. The patent will provide protection until 2032.

May 12

2016

SAN DIEGO, May 12, 2016 —Edico Genome, creator of the world’s first bio-IT processor designed to analyze next-generation sequencing data, today announced a collaboration with IBM to make DRAGEN available on the new IBM Power Systems S822LC for high performance computing (HPC).

In addition, Edico is now offering the Broad Institute’s Genome Analysis Toolkit (GATK), a software package for analysis of high-throughput sequencing data, deployed on DRAGEN. Called Accelerated GATK, internal testing by Edico suggests that the offering takes only 18 minutes to complete variant calling analysis when run on the IBM Power Systems S822LC for HPC, which in the past has taken approximately 30 hours.

Apr 13

2016

SAN DIEGO, April 13, 2016 – Edico Genome today announced that Kirk D. Malloy, Ph.D., most recently the senior vice president and general manager of life sciences and applied markets at Illumina, Inc., has been appointed to the company’s board of directors. Dr. Malloy brings over twenty years of experience in life science executive leadership and management to Edico Genome’s board of directors, which includes Gregory T. Lucier, former chairman and chief executive officer of Life Technologies, Kenneth F. Buechler, Ph.D., co-founder and former president and chief scientific officer of Biosite Incorporated, Mark Bowles, co-founder of SalveoDx and Eco-ATM and Pieter van Rooyen, Ph.D., co-founder, president and chief executive officer of Edico Genome.

Jan 11

2016

SEOUL, South Korea and SAN DIEGO, Jan. 11, 2016 — Macrogen, a global leader in genome sequencing services, and Edico Genome today announced Macrogen has chosen multiple DRAGEN™ Bio-IT Processors to reinforce its big data processing and analysis capacity for large-scale genome analysis and clinical sequencing services. Macrogen has world-class next-generation sequencing (NGS) facilities, which are equipped with Illumina’s HiSeq™ X Ten, HiSeq 2000, HiSeq 2500, HiSeq 4000 and MiSeq® sequencing systems; Thermo Fisher’s Ion PGM™ and Ion Proton™ systems; Roche’s GS-FLX system; and PacBio instruments. Macrogen’s IT infrastructure capacity exceeds 11 petabytes of storage and more than 3,000 core clusters. Using DRAGEN, Macrogen was able to analyze each genome (30x coverage) produced by their HiSeq X Ten sequencing system in only 26 minutes, while maintaining high sensitivity and specificity. This analysis included conversion from BCL, the file that is delivered by the sequencing instrument, to variant call format (VCF).

Oct 28

2015

The Genome Analysis Centre (TGAC) is the first institute in the U.K. to deploy a new bioinformatics processor called DRAGEN™, which dramatically reduces genomic pipeline runtimes from hours to minutes. This collaboration between Edico Genome and TGAC resulted in the first adaptation of the DRAGEN technology for the analysis of non-human genomes as part of the Institute’s endeavours to sequence the DNA of plant, animal and microbial species to promote a sustainable bioeconomy.

NORWICH, England and SAN DIEGO, Oct. 28, 2015 — TGAC’s high performance computing (HPC) infrastructure will benefit from the addition of Edico Genome’s DRAGEN™, the world’s first processor designed to analyse specific sequencing data tasks. DRAGEN will be used to accelerate TGAC’s next-generation sequencing workflows.

Initial evaluations of DRAGEN showed that mapping against the ash tree genome was 177 times faster per processing core than TGAC’s local HPC systems, requiring only 7 minutes instead of 3 hours on one of the larger datasets. Alignment runs on the rice genome that take approximately two hours on TGAC’s HPC servers took just three minutes using DRAGEN.

Oct 9

2015

SAN DIEGO, Oct. 9, 2015 — The Centers for Disease Control and Prevention, through the National Center for Emerging and Zoonotic Infectious Diseases, Office of Advanced Molecular Detection (OAMD), and Edico Genome have entered into a research collaboration to evaluate the performance of Edico Genome’s DRAGEN hardware platform. The goal of this research collaboration is to evaluate the utility of the Edico Genome DRAGEN platform for public health and infectious disease applications. This collaboration will also focus on co-developing the databases, configurations and parameters to optimize the hardware platform for microbial applications.

Sep 29

2015

KANSAS CITY, Mo. and SAN DIEGO, Sept. 29, 2015 — Rapid diagnosis is essential in acute care situations, particularly in neonatal intensive care units where medical decision-making must happen in minutes and hours, not weeks. Today, Children’s Mercy Kansas City and Edico Genome published results of a study showing the successful diagnosis of critically ill newborns in just 26 hours using a new genomic data analysis technology, DRAGEN™, and optimizing other parameters. Prior to this study, published Sept. 29 in Genome Medicine, the world’s fastest diagnosis of critically ill newborns using whole genome sequencing was 50 hours.

Sep 9

2015

One DRAGEN Processor Analyzes 15,000 Human Genomes Generated by Institute’s Illumina HiSeq X Ten Sequencing System

Technology Utilized in Genomic Services Laboratory, Clinical Services Laboratory, CSER Consortium Work

HUNTSVILLE, Ala. and SAN DIEGO, Sept. 9, 2015 — Edico Genome today announced that its DRAGEN™ Bio-IT Processor has been integrated into HudsonAlpha Institute for Biotechnology’s next-generation sequencing workflow, thereby increasing the throughput of the sequencing facility and eliminating the need for expensive servers. A single DRAGEN processor is able to analyze the 15,000 human genomes generated by the institute’s HiSeq X Ten sequencing system, manufactured by Illumina Inc. As part of the DRAGEN integration, HudsonAlpha developed a front-end management system to enable robust and automated transfer of data from a collection of sequencers to the processor, and automated reporting of results at the conclusion of the analysis.

May 6

2015

Processor Accelerates Analysis Times by 60 Fold for Whole Genome and Whole Exome Sequencing, Maintains Greater than 99 Percent Sensitivity

SAN DIEGO,May 6, 2015 – Edico Genome today announced that PerkinElmer, Inc. has purchased a DRAGEN™ Bio-IT processor to expedite the analysis of its customers’ next-generation sequencing (NGS) data. Applying the processor to PerkinElmer’s NGS workflow, DRAGEN accelerates analysis time for whole genome and whole exome sequencing 60 fold, compared to standard industry software, while maintaining greater than 99 percent sensitivity. The processor will be integrated into PerkinElmer’s CLIA-certified, high-throughput sequencing facility.

Apr 27

2015

Results Achieved in Approximately Six Hours, Compared to 60 Hours with Standard Software

SAN DIEGO, April 27, 2015 – Edico Genome today announced that collaborative data generated with biochemists and geneticists from Harvard and Stanford Universities showed the DRAGEN™ Bio-IT Processor sped analysis of a whole genome sequence with 300x depth of coverage by tenfold, generating results in approximately six hours compared to 60 hours with standard software.

Apr 22

2015

SAN DIEGO, April 22, 2015  — Edico Genome, developer of the world’s first Bio-IT Processor, DRAGEN™, a solution that enables fast and cost-effective analysis of next-generation sequencing (NGS) data, today announced the United States Patent and Trademark Office has issued to the company U.S. patent number 9,014,989. This patent broadly covers proprietary processes that are core to DRAGEN, including bioinformatics protocols and functions necessary for the analysis of genomic data on integrated circuits and hardware processing platforms. The patent will provide protection until 2035 and is entitled “Bioinformatics Systems, Apparatuses, and Methods Executed on an Integrated Circuit Processing Platform.”

Apr 21

2015

SAN DIEGO, April 21, 2015 – Edico Genome today announced a collaboration with Intel Corporation to develop solutions with Intel’s Xeon processors to accelerate next generation sequencing (NGS) data analysis. The resulting solution will enable completion of primary and secondary NGS analysis in real time, while sustaining superior accuracy, decreasing costs, streamlining data analysis in the cloud and holds benefits for applications that require sharing of big data sets, such as analysis of population-scale genomic data.

Oct 13

2014

Rapid Analysis of Next-Generation Sequencing Data to be Demonstrated at the American Society of Human Genetics (ASHG) 2014 Annual Meeting

SAN DIEGO, Oct. 13, 2014 – Edico Genome today announced the DRAGEN™ Bio-IT Processor, the world’s first bioinformatics application-specific integrated circuit (ASIC), which is embedded on a PCIe form factor card and accompanied with software as a Platform-as-a-Service (PaaS), is now broadly available to clinical labs and researchers utilizing next-generation sequencing instruments. The impact of the speed and compact size of DRAGEN will be demonstrated at the American Society of Human Genetics 2014 Annual Meeting, taking place Oct. 18-22 in San Diego. Results from a study conducted with Sequenom Laboratories, a recent customer, comparing results between Sequenom Laboratories’ current analysis pipeline and the results using DRAGEN, will also be presented.

Sep 3

2014

SAN DIEGO, Sept. 3, 2014 – Edico Genome today announced that Sequenom, Inc., a life sciences company that provides innovative genetic analysis solutions, purchased an Edico Genome DRAGEN™ Bio-IT Processor. The DRAGEN Bio-IT Processor is the world’s first next-generation sequencing bioinformatics application-specific integrated circuit (ASIC), which is embedded on a PCIe form factor card and accompanied with software as a Platform-as-a-Service (PaaS) platform. The two companies recently completed a proof-of-concept study, comparing results between Sequenom Laboratories’ (a wholly owned subsidiary of Sequenom, Inc.) current analysis pipeline and the results using DRAGEN.

Jul 17

2014

Led by Qualcomm, Gregory Lucier Makes First Investment after Leading Life Technologies

SAN DIEGO, July 17, 2014 — Edico Genome announced today that it has raised $10 million in a Series A financing to commercialize its DRAGEN™ Bio-IT Processor, the world’s first next-generation sequencing bioinformatics application-specific integrated circuit (ASIC). The financing was led by Qualcomm Incorporated, through its venture investment group, Qualcomm Ventures, and included Axon Ventures and Greg Lucier, who made his first investment following his role as chairman and chief executive officer of Life Technologies. Concurrent with the financing, Mr. Lucier was appointed to the Edico Genome board of directors. Advisory board members include Eric Topol, M.D., professor of genomics, The Scripps Research Institute, Charles Cantor, Ph.D., chief scientific officer, Sequenom, and Nils Homer, Ph.D., genomics informatics leader, Broad Institute. The financing will be used for commercialization of DRAGEN, which is expected to broadly launch at the American Society of Human Genetics annual meeting in October.